Resende, C B <br/><br/>
Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation.  [electronic resource] 

 -  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas  Feb 2017 
 - e5566 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1414-431X 
<br/><br/><label>Standard No.: </label>10.1590/1414-431X20165566  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Alemtuzumab<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Child<br/>Child, Preschool<br/>Cytomegalovirus--physiology<br/>Cytomegalovirus Infections--prevention & control<br/>Disease-Free Survival<br/>Female<br/>Graft vs Host Disease--prevention & control<br/>Hematopoietic Stem Cell Transplantation--adverse effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Risk Factors<br/>Transplantation, Homologous<br/>Virus Activation--drug effects<br/>Young Adult